AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3578852
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of 0.25% bupivacaine with 1:300,000 epinephrine
Trial: 31674058
Drug: VIT-2763 5/15/60/120/240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIT-2763 5/15/60/120/240 mg (SAD phase)
Trial: 31674058
Drug: VIT-2763 60/120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIT-2763 60/120 mg once daily (MAD phase)
Trial: 31674058
Drug: VIT-2763 60/120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIT-2763 60/120 mg twice daily (MAD phase)
Trial: 31674058
Drug: VIT-2763 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIT-2763 (all doses)
Trial: 31674058
Drug: VIT-2763 120
RxNorm normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VIT-2763 120 mg once daily (MAD phase)
Trial: 27893567
Drug: Usual ambulatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual ambulatory physical therapy (PT) (n = 43).
Trial: 26293170
Drug: adapalene gel
RxNorm normalized name: Adapalene Gel
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: adapalene gel with the active formulation
Trial: 26293170
Drug: adapalene gel
RxNorm normalized name: Adapalene Gel
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: adapalene gel with the placebo
Trial: 26293170
Drug: adapalene gel
RxNorm normalized name: Adapalene Gel
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: adapalene gel
Trial: 12915819
Drug: Ganciclovir therapy
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ganciclovir therapy (6 weeks of intravenous ganciclovir)
Trial: 12915819
Drug: Ganciclovir therapy
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ganciclovir therapy
Trial: 10574621
Drug: Neutrophil-derived serine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutrophil-derived serine proteases (elastase, cathepsin G, proteinase 3)
Trial: 10574621
Drug: Cathepsin G
RxNorm normalized name: Cathepsin G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cathepsin G
Trial: 29893769
Drug: Palbociclib 125
RxNorm normalized name: palbociclib 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palbociclib 125 mg daily for 14 days
Trial: 20167446
Drug: Cooled water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cooled water pillow (15 degrees C) for 48 hours with restricted activity and medication (60 mg of prednisone for 7 days)
Trial: 20167446
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received only medication (60 mg of prednisone for 7 days) without cooling and rest
Trial: 12566475
Drug: Protein Group
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein Group (1.6 g/(kg. d); CHO <40% of energy)
Trial: 12566475
Drug: CHO Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO Group (0.8 g/(kg. d); CHO >55%)
Trial: 1912753
Drug: Naltrexone (350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (350 mg per week for 1 month, then random allocation to naltrexone for 6 months)
Trial: 6756833
Drug: 40-g/day vegetable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40-g/day vegetable protein diet
Trial: 6756833
Drug: 80-g/day vegetable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80-g/day vegetable protein diet
Trial: 6756833
Drug: 40-g/day meat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40-g/day meat protein diet plus neomycin-milk of magnesia
Trial: 26111609
Drug: Enoxaparin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (20 mg, subcutaneous, every 12 h from postoperative day 2 to 8)
Trial: 21390056
Drug: Indapamide slow
RxNorm normalized name: Indapamide
DrugBank: Indapamide (DB00808)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indapamide slow release 1.5 mg, indapamide plus 2 mg perindopril, and indapamide plus 4 mg perindopril
Trial: 21390056
Drug: Indapamide plus
RxNorm normalized name: Indapamide
DrugBank: Indapamide (DB00808)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indapamide plus 2 mg perindopril
Trial: 21390056
Drug: Indapamide plus
RxNorm normalized name: Indapamide
DrugBank: Indapamide (DB00808)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indapamide plus 4 mg perindopril
Trial: 17688720
Drug: Calculated intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calculated intravenous crystalloid based on body weight (group 2)
Trial: 8059811
Drug: Metronidazole (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (250 mg three times a day for 7 days)
Trial: 2648511
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of isoniazid, rifampicin, and pyrazinamide (fixed proportions)
Trial: 2648511
Drug: Separate tablets
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate tablets of isoniazid, rifampicin, and pyrazinamide
Trial: 5338884
Drug: Ro 4‐5360,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 4‐5360, 10 mg. (Mogadon)
Trial: 5338884
Drug: methyprylon, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methyprylon, 200 mg. (Noludar)
Trial: 5338884
Drug: Ro 4‐5360,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 4‐5360, 5 mg. (Mogadon)
Trial: 5338884
Drug: secobarbital sodium,
RxNorm normalized name: Secobarbital Sodium, 50 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: secobarbital sodium, 100 mg. (Seconal)
Trial: 28455295
Drug: Low stroke
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low stroke volume indexed for body surface area (SVI) defined as <35 mL/m2
Trial: 23716516
Drug: Hydration (drank
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydration (drank 250 mL of water at 15‐minute intervals, totaling 1000 mL/h)
Trial: 16779972
Drug: Fluoride varnish
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride varnish applied to experimental dental quadrants every 3 months during 12 months of orthodontic treatment
Trial: 14699594
Drug: Plasma exchange
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma exchange (PE) treatment for one or two consecutive sessions
Trial: 9360001
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg reserpine plus 5 mg clopamide (R/C)
Trial: 9360001
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg enalapril
Trial: 29856470
Drug: Adrecizumab (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrecizumab (various doses)
Trial: 26666481
Drug: High TEWL
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High TEWL group (TEWL > 6.5 g/m(2)/h)
Trial: 26666481
Drug: Daily emollient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily emollient use in high TEWL group
Trial: 15615797
Drug: Conservative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative therapy (no-PCI)
Trial: 14969077
Drug: Adalimumab 20
RxNorm normalized name: ADALIMUMAB 20MG/0.4ML INJ SYRINGE KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 20 mg once a week
Trial: 10382902
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human G‐CSF (rhG‐CSF)
Trial: 8886213
Drug: Naprelan 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naprelan 1,000 mg once daily
Trial: 8886213
Drug: Naprelan 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naprelan 1,000 mg once daily (open-label phase)
Trial: 8886213
Drug: Naprosyn 500
RxNorm normalized name: Naprosyn 500mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naprosyn 500 mg BID (open-label phase)
Trial: 27317505
Drug: Classification-specific treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classification-specific treatment (CS)
Trial: 27317505
Drug: Non classification-specific
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non classification-specific treatment (NCs)
Trial: 20025989
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg three days a week for 6 months
Trial: 12492726
Drug: Desloratadine 5
RxNorm normalized name: desloratadine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desloratadine 5 mg single dose
Trial: 12492726
Drug: Desloratadine 5
RxNorm normalized name: desloratadine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desloratadine 5 mg once daily for 7 days
Trial: 9618124
Drug: Dietary fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary fat restriction (22 g/day to 26 g/day)
Trial: 7623005
Drug: Inactivated hepatitis
RxNorm normalized name: Inactivated hepatitis A vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated hepatitis A vaccine (720 ELISA units of hepatitis A antigen per dose)
Trial: 14971532
Drug: 50 mg/day
RxNorm normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/day of Pueraria mirifica (Group A)
Trial: 14971532
Drug: 100 mg/day
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/day of Pueraria mirifica (Group B)
Trial: 14971532
Drug: Pueraria mirifica
RxNorm normalized name: PUERARIA MIRIFICA ROOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pueraria mirifica (both doses)
Trial: 9469523
Drug: Flurbiprofen (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen (200 mg orally)
Trial: 2821080
Drug: Enalapril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (5 mg twice daily, maximum dose = 40 mg/d)
Trial: 2821080
Drug: Metoprolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (50 mg twice daily, maximum dose = 400 mg/d)
Trial: 29042000
Drug: NBR biofeedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NBR biofeedback plus topiramate 50 mg (b.i.d.)
Trial: 29042000
Drug: Topiramate 50
RxNorm normalized name: topiramate 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate 50 mg (b.i.d.)
Trial: 26178748
Drug: Nerve Growth
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerve Growth Factor (NGF) injection into extensor carpi radialis brevis (ECRB) muscle
Trial: 26178748
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline injection into extensor carpi radialis brevis (ECRB) muscle
Trial: 17991805
Drug: Replacement therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Replacement therapy for SCTD; specific dosage and duration not mentioned.
Trial: 16259942
Drug: Habit reversal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Habit reversal therapy (HR)
Trial: 11329490
Drug: 4-methylpyrazole (4-MP)
RxNorm normalized name: 4-methylpyrazol
DrugBank: Fomepizole (DB01213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-methylpyrazole (4-MP) 10-15 mg/kg p.o.
Trial: 7962671
Drug: Bisoprolol hemifumarate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol hemifumarate (5 to 40 mg)
Trial: 2891536
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg oxmetidine
Trial: 2891536
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg oxmetidine
Trial: 8054436
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for Toxoplasma gondii
Trial: 31319637
Drug: Bupivacaine 0.5%
RxNorm normalized name: BUPivacaine 0.5% injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.5% (12.5 mg, 2.5 mL)
Trial: 24048551
Drug: BST‐CarGel treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BST‐CarGel treatment (n = 41)
Trial: 24048551
Drug: Microfracture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microfracture treatment alone (n = 39)
Trial: 21639636
Drug: Culturally Informed
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally Informed and Flexible Family‐Based Treatment for Adolescents (CIFFTA)
Trial: 21639636
Drug: Traditional Family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Family Therapy (TFT)
Trial: 19736179
Drug: Self-treatment of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-treatment of exacerbations with an action plan including prednisolone (with or without antibiotics).
Trial: 19736179
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no self-treatment training).
Trial: 19736179
Drug: Self-treatment group.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-treatment group.
Trial: 9282449
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (third group)
Trial: 9282449
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (fourth group)
Trial: 8380610
Drug: Ganciclovir (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganciclovir (5 mg/kg every 12 hours for 14 days)
Trial: 28851099
Drug: 2-ml autologous
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-ml autologous platelet-rich plasma (PRP) injection
Trial: 28851099
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy without injection (Control)
Trial: 18486923
Drug: Monoclonal antibodies
RxNorm normalized name: Monoclonal antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibodies targeting adhesion molecules
Trial: 17699341
Drug: Satavaptan 25
RxNorm normalized name: Satavaptan
DrugBank: Satavaptan (DB14923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Satavaptan 25 mg
Trial: 17699341
Drug: Satavaptan 50
RxNorm normalized name: Satavaptan
DrugBank: Satavaptan (DB14923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Satavaptan 50 mg
Trial: 17699341
Drug: Long-term treatment
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term treatment with Satavaptan
Trial: 12689734
Drug: Antiretroviral drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral drugs (specific drugs and dosages not mentioned)
Trial: 1546124
Drug: Moclobemide 450
RxNorm normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide 450 mg/day
Trial: 8923574
Drug: Moclobemide 600
RxNorm normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide 600 mg/day
Trial: 8923574
Drug: Moclobemide (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide (all doses)
Trial: 2986508
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir (400 mg five times daily for 10 days)
Trial: 12060512
Drug: Topical ALA-PDT
RxNorm normalized name: Ala-Cort Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ALA-PDT
Trial: 2360741
Drug: Calcium chloride
RxNorm normalized name: Calcium Chloride
DrugBank: Calcium chloride (DB01164)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium chloride (10 mg/kg, n = 8)
Trial: 2360741
Drug: Calcium gluconate
RxNorm normalized name: Calcium Gluconate
DrugBank: Calcium gluconate (DB11126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium gluconate (30 mg/kg, n = 7)
Trial: 23842536
Drug: Intranasal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal fentanyl (1.5 microgram/kg)
Trial: 19361362
Drug: Integrated traditional
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated traditional Chinese and Western medicine therapy without antibiotics
Trial: 19361362
Drug: Imipenem‐cilastatin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem‐cilastatin (0.5 g every eight hours for ten days)
Trial: 11059520
Drug: Inhaled glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled glucocorticoid therapy
Trial: 11059520
Drug: Systemic glucocorticoid
RxNorm normalized name: Glucocorticoids, Systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic glucocorticoid therapy
Trial: 1412754
Drug: Double therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double therapy with cyclosporine and prednisolone
Trial: 1412754
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with cyclosporine, azathioprine, and prednisolone
Trial: 1412754
Drug: Double therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double therapy with cyclosporine and prednisolone (subgroup with azathioprine)
Trial: 30474791
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (100 ml saline solution)
Trial: 28412755
Drug: Intravenous propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous propofol anesthesia (group P, n = 25)
Trial: 21677059
Drug: 4% l-arabinose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% l-arabinose in sucrose beverages
Trial: 21677059
Drug: Control (0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0% l-arabinose in sucrose beverages)
Trial: 16952809
Drug: Perineural space
RxNorm normalized name: ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perineural space expansion with 10 mL dextrose 5% in water (D5W) flush before catheter placement
Trial: 9444798
Drug: Non-specific support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-specific support therapy (control)
Trial: 7942533
Drug: 324 mg
RxNorm normalized name: aspirin 324 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 324 mg aspirin
Trial: 7942533
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of aspirin (81, 162, 324 mg)
Trial: 3203047
Drug: Inhaled ouabain
RxNorm normalized name: ouabain
DrugBank: Ouabain (DB01092)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled ouabain (1 mg)
Trial: 20058619
Drug: Control (non-metformin)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (non-metformin)
Trial: 10917406
Drug: ACTH 4-10
RxNorm normalized name: ACTH
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACTH 4-10 (1 mg single dose)
Trial: 10917406
Drug: ACTH 4-10
RxNorm normalized name: ACTH
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACTH 4-10 (1 mg/day for 6 weeks)
Trial: 10917406
Drug: Desacetyl-alpha-MSH (equimolar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desacetyl-alpha-MSH (equimolar doses)
Trial: 3582518
Drug: Theophylline therapy
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline therapy (5 days oral administration)
Trial: 12847070
Drug: Tenecteplase +
RxNorm normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenecteplase + Enoxaparin (30 mg IV bolus followed by 1 mg/kg SC BID for 7 days)
Trial: 12847070
Drug: Tenecteplase +
RxNorm normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenecteplase + Unfractionated Heparin (UFH)
Trial: 7793887
Drug: Itraconazole 100
RxNorm normalized name: itraconazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 100 mg daily oral doses for at least 3 weeks
Trial: 2338029
Drug: Intravenous S/A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous S/A (1.0/2.0 g)
Trial: 2338029
Drug: Intravenous S/A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous S/A (0.5/1.0 g)
Trial: 2338029
Drug: Intramuscular S/A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular S/A (0.5/1.0 g)
Trial: 380913
Drug: Indomethacin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (25 mg 3-times daily)
Trial: 380913
Drug: Ibuprofen (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (400 mg 3-times daily)
Trial: 27733180
Drug: linagliptin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: linagliptin (5 mg) administered once daily for 12 weeks
Trial: 25675797
Drug: Early oral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early oral feeding (EOF) after regional anesthesia (n=49)